Tiziana Life Sciences Ltd. announced for the first time, quantitative data showing improvement in White Matter Z scores measured from PET images taken at 3 months in nasal foralumab treated patients with non-active secondary progressive multiple sclerosis (na-SPMS). White Matter Z scores are a statistical measure used in neuroimaging studies to assess the integrity or abnormalities in structures of the brain.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8099 USD | +9.34% | +8.86% | +44.62% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+44.62% | 81.24M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- TLSA Stock
- News Tiziana Life Sciences Ltd
- Tiziana Life Sciences Ltd Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab